1. clinical signs indicative of severe or critical covid-19 disease (eg, oxygen saturation \< 94% on room air or respiration rate \> 30 bpm) 2. pregnant or lactating women who are breastfeeding 3. use of systemic glucocorticoid medications in the last six months 4. recent history (previous 12 months) of primary hyperparathyroidism, kidney stones, hypercalciuria and/or hypercalcemia 5. history of a chronic granuloma-forming disease (eg, sarcoidosis) 6. history of tuberculosis or histoplasmosis 7. history of chronic liver disease 8. history (previous 12 months) of cardiac event indicative of chronic cardiovascular diseases including congestive heart failure, poorly controlled hypertension and arrhythmias 9. history in the past five years of multiple myeloma or carcinoma of the breast, lung or prostate 10. any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of vitamin d or 25-hydroxyvitamin d (25d) (eg, small bowel resection, history of crohn's disease or ulcerative colitis) 11. ongoing treatment with thiazide diuretics 12. history of hyperphosphatemia, hyperuricemia and gout 13. renal impairment measured as egfr\< 15 ml/min/1.73m² on serum creatinine in the last three months 14. serum calcium ≥9.8 mg/dl in the last three months 15. evidence of existing or impending dehydration 16. known or suspected to have hypersensitivity to any of the constituents of the study drug 17. currently participating in, or have participated in, an interventional/investigational study within 30 days prior to study screening.

1. clinical signs indicative of severe or critical covid-19 disease (eg, oxygen saturation \< 94% on room air or respiration rate \> 30 bpm) 2. pregnant or lactating women who are breastfeeding 3. use of systemic glucocorticoid medications in the last six months 4. recent history (previous 12 months) of primary hyperparathyroidism, kidney stones, hypercalciuria and/or hypercalcemia 5. history of a chronic granuloma-forming disease (eg, sarcoidosis) 6. history of tuberculosis or histoplasmosis 7. history of chronic liver disease 8. history (previous 12 months) of cardiac event indicative of chronic cardiovascular diseases including congestive heart failure, poorly controlled hypertension and arrhythmias 9. history in the past five years of multiple myeloma or carcinoma of the breast, lung or prostate 10. any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of vitamin d or 25-hydroxyvitamin d (25d) (eg, small bowel resection, history of crohn's disease or ulcerative colitis) 11. ongoing treatment with thiazide diuretics 12. history of hyperphosphatemia, hyperuricemia and gout 13. renal impairment measured as egfr\< 15 ml/min/1.73m² on serum creatinine in the last three months 14. serum calcium ≥9.8 mg/dl in the last three months 15. evidence of existing or impending dehydration 16. known or suspected to have hypersensitivity to any of the constituents of the study drug 17. currently participating in, or have participated in, an interventional/investigational study within 30 days prior to study screening.

clinical signs indicative of severe or critical covid-19 disease (eg, oxygen saturation < 94% on room air or respiration rate > 30 bpm) pregnant or lactating women who are breastfeeding use of systemic glucocorticoid medications in the last six months recent history (previous 12 months) of primary hyperparathyroidism, kidney stones, hypercalciuria and/or hypercalcemia history of a chronic granuloma-forming disease (eg, sarcoidosis) history of tuberculosis or histoplasmosis history of chronic liver disease history (previous 12 months) of cardiac event indicative of chronic cardiovascular diseases including congestive heart failure, poorly controlled hypertension and arrhythmias history in the past five years of multiple myeloma or carcinoma of the breast, lung or prostate any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of vitamin d or 25-hydroxyvitamin d (25d) (eg, small bowel resection, history of crohn's disease or ulcerative colitis) ongoing treatment with thiazide diuretics history of hyperphosphatemia, hyperuricemia and gout renal impairment measured as egfr< 15 ml/min/1.73m² on serum creatinine in the last three months serum calcium ≥9.8 mg/dl in the last three months evidence of existing or impending dehydration known or suspected to have hypersensitivity to any of the constituents of the study drug currently participating in, or have participated in, an interventional/investigational study within 30 days prior to study screening.

clinical signs indicative of severe or critical covid-19 disease (eg, oxygen saturation < 94% on room air or respiration rate > 30 bpm) pregnant or lactating women who are breastfeeding use of systemic glucocorticoid medications in the last six months recent history (previous 12 months) of primary hyperparathyroidism, kidney stones, hypercalciuria and/or hypercalcemia history of a chronic granuloma-forming disease (eg, sarcoidosis) history of tuberculosis or histoplasmosis history of chronic liver disease history (previous 12 months) of cardiac event indicative of chronic cardiovascular diseases including congestive heart failure, poorly controlled hypertension and arrhythmias history in the past five years of multiple myeloma or carcinoma of the breast, lung or prostate any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of vitamin d or 25-hydroxyvitamin d (25d) (eg, small bowel resection, history of crohn's disease or ulcerative colitis) ongoing treatment with thiazide diuretics history of hyperphosphatemia, hyperuricemia and gout renal impairment measured as egfr< 15 ml/min/1.73m² on serum creatinine in the last three months serum calcium ≥9.8 mg/dl in the last three months evidence of existing or impending dehydration known or suspected to have hypersensitivity to any of the constituents of the study drug currently participating in, or have participated in, an interventional/investigational study within 30 days prior to study screening.

clinical signs indicative of severe or critical covid-19 disease (eg, oxygen saturation < 94% on room air or respiration rate > 30 bpm) pregnant or lactating women who are breastfeeding use of systemic glucocorticoid medications in the last six months recent history (previous 12 months) of primary hyperparathyroidism, kidney stones, hypercalciuria and/or hypercalcemia history of a chronic granuloma-forming disease (eg, sarcoidosis) history of tuberculosis or histoplasmosis history of chronic liver disease history (previous 12 months) of cardiac event indicative of chronic cardiovascular diseases including congestive heart failure, poorly controlled hypertension and arrhythmias history in the past five years of multiple myeloma or carcinoma of the breast, lung or prostate any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of vitamin d or 25-hydroxyvitamin d (eg, small bowel resection, history of crohn's disease or ulcerative colitis) ongoing treatment with thiazide diuretics history of hyperphosphatemia, hyperuricemia and gout renal impairment measured as egfr< 15 ml/min/1.73m² on serum creatinine in the last three months serum calcium ≥9.8 mg/dl in the last three months evidence of existing or impending dehydration known or suspected to have hypersensitivity to any of the constituents of the study drug currently participating in, or have participated in, an interventional/investigational study within 30 days prior to study screening.

clinical signs indicative of severe or critical covid-19 disease (eg, oxygen saturation < 94% on room air or respiration rate > 30 bpm) pregnant or lactating women who are breastfeeding use of systemic glucocorticoid medications in the last six months recent history (previous 12 months) of primary hyperparathyroidism, kidney stones, hypercalciuria and/or hypercalcemia history of a chronic granuloma-forming disease (eg, sarcoidosis) history of tuberculosis or histoplasmosis history of chronic liver disease history (previous 12 months) of cardiac event indicative of chronic cardiovascular diseases including congestive heart failure, poorly controlled hypertension and arrhythmias history in the past five years of multiple myeloma or carcinoma of the breast, lung or prostate any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of vitamin d or 25-hydroxyvitamin d (eg, small bowel resection, history of crohn's disease or ulcerative colitis) ongoing treatment with thiazide diuretics history of hyperphosphatemia, hyperuricemia and gout renal impairment measured as egfr< 15 ml/min/1.73m² on serum creatinine in the last three months serum calcium ≥9.8 mg/dl in the last three months evidence of existing or impending dehydration known or suspected to have hypersensitivity to any of the constituents of the study drug currently participating in, or have participated in, an interventional/investigational study within 30 days prior to study screening.

1. clinical signs indicative of severe or critical covid-19 disease (eg, oxygen saturation < 94% on room air or respiration rate > 30 bpm) 2. pregnant or lactating women who are breastfeeding 3. use of systemic glucocorticoid medications in the last six months 4. recent history (previous 12 months) of primary hyperparathyroidism, kidney stones, hypercalciuria and/or hypercalcemia 5. history of a chronic granuloma-forming disease (eg, sarcoidosis) 6. history of tuberculosis or histoplasmosis 7. history of chronic liver disease 8. history (previous 12 months) of cardiac event indicative of chronic cardiovascular diseases including congestive heart failure, poorly controlled hypertension and arrhythmias 9. history in the past five years of multiple myeloma or carcinoma of the breast, lung or prostate 10. any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of vitamin d or 25-hydroxyvitamin d (eg, small bowel resection, history of crohn's disease or ulcerative colitis) 11. ongoing treatment with thiazide diuretics 12. history of hyperphosphatemia, hyperuricemia and gout 13. renal impairment measured as egfr< 15 ml/min/1.73m² on serum creatinine in the last three months 14. serum calcium ≥9.8 mg/dl in the last three months 15. evidence of existing or impending dehydration 16. known or suspected to have hypersensitivity to any of the constituents of the study drug 17. currently participating in, or have participated in, an interventional/investigational study within 30 days prior to study screening.

1. clinical signs indicative of severe or critical covid-19 disease (eg, oxygen saturation < 94% on room air or respiration rate > 30 bpm) 2. pregnant or lactating women who are breastfeeding 3. use of systemic glucocorticoid medications in the last six months 4. recent history (previous 12 months) of primary hyperparathyroidism, kidney stones, hypercalciuria and/or hypercalcemia 5. history of a chronic granuloma-forming disease (eg, sarcoidosis) 6. history of tuberculosis or histoplasmosis 7. history of chronic liver disease 8. history (previous 12 months) of cardiac event indicative of chronic cardiovascular diseases including congestive heart failure, poorly controlled hypertension and arrhythmias 9. history in the past five years of multiple myeloma or carcinoma of the breast, lung or prostate 10. any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of vitamin d or 25-hydroxyvitamin d (eg, small bowel resection, history of crohn's disease or ulcerative colitis) 11. ongoing treatment with thiazide diuretics 12. history of hyperphosphatemia, hyperuricemia and gout 13. renal impairment measured as egfr< 15 ml/min/1.73m² on serum creatinine in the last three months 14. serum calcium ≥9.8 mg/dl in the last three months 15. evidence of existing or impending dehydration 16. known or suspected to have hypersensitivity to any of the constituents of the study drug 17. currently participating in, or have participated in, an interventional/investigational study within 30 days prior to study screening.